Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.
about
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITDRelapsed acute myeloid leukemia: why is there no standard of care?Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemiaAdvances in treating acute myeloid leukemia.FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasmInhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cellsFLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotypeFLT3/ITD AML and the law of unintended consequences.Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.A novel somatic mutation in ACD induces telomere lengthening and apoptosis resistance in leukemia cellsImprovement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.Salvage therapy for relapsed or refractory acute myeloid leukemiaPotential of whole-genome sequencing for determining risk and personalizing therapy: focus on AMLPhase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationEffect of FLT3 ligand on survival and disease phenotype in murine models harboring a FLT3 internal tandem duplication mutation.Recent advances and novel agents for FLT3 mutated acute myeloid leukemia.Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia.How I treat FLT3-mutated AML.NT1721, a novel epidithiodiketopiperazine, exhibits potent in vitro and in vivo efficacy against acute myeloid leukemia.The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia.The clinical development of FLT3 inhibitors in acute myeloid leukemia.Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.FLT3 inhibitors in AML: are we there yet?Targeting FLT3 to treat leukemia.Acute myeloid leukemia--major progress over four decades and glimpses into the future.Inhibition of FLT3 in AML: a focus on sorafenib.Outcome of older patients with acute myeloid leukemia in first relapse.Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics.Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant.Association of polymorphisms in FLT3, EGFR, ALOX5, and NEIL3 with glioblastoma in the Han Chinese population.Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients.Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AMLSelf-nanoemulsifying system improves oral absorption and enhances anti-acute myeloid leukemia activity of berberine
P2860
Q33798909-EE5E39B9-8D5B-4866-B308-EC7E58D7F08BQ33877202-E8785211-554C-4EA8-9D86-4E6CE5833154Q34004131-8A4455CD-49E2-4A9E-A590-F11593C11CA8Q34312351-2789E035-2FF8-4DDC-A2A4-E82660FC9ACFQ34408941-54E102E7-D6B0-4793-8781-716E176C5B29Q34805329-A24CCE83-4B23-4CF7-BFAC-EB0A11737400Q34890418-D7D9C9A1-9BA3-4EE0-9452-0F167D2B0BD2Q35127958-77D0BA38-BFBF-4244-B9AC-7EB7B88799B5Q35224437-A6348083-890E-4DA9-AEA4-023A8FA742DBQ35765789-B81CC479-F37A-4C31-AFBE-2C4C802E1F02Q36200300-C35978E0-2CBC-4C9E-AA76-F41ED492C70AQ36612564-C8FE71BB-E3F0-4019-AFFF-6F0C7319AF35Q36797201-45FEFCBE-3CAB-4D7A-9939-ECB0089C9B45Q36907832-A8E1EC0E-0F49-4F17-83A8-F92CDD983E35Q36949028-84CA1B07-DFC4-4CD2-82D4-3E4ABF17E51FQ37043763-94134E86-0608-4594-95B1-AE4F811C035CQ37235671-A7CD875C-FBE0-448A-AA90-E8328DE56FDCQ37623389-A1529410-5EF5-475D-80F9-3556321D566CQ37699211-9BBFAEEB-8683-4566-BEBE-5FB35B3452C0Q37706488-39B709E2-77CB-4B61-9B42-0C7B70DD7696Q37927089-C2C0E25E-77F5-4CAE-8F24-2EDEB0B4448FQ38011962-78D91C18-EC72-4DCF-97D9-AED3CCA7A30EQ38200564-DE7902D2-EB89-48DA-AB09-9DAFCD4B42AEQ38251339-5F069F63-227B-4755-8AEA-9C49E76942CFQ38644941-C8210D5E-0483-41B2-A8C9-406F486394EAQ38989349-41E8EA1B-FDF2-4A75-B100-A4AE5C05DB12Q39405204-08E90734-E918-4C66-8167-FF8A7B5F7B78Q39674948-4CB90F4F-4D39-42AC-BAF9-C0F489387D30Q42142418-375B34C4-8FF4-4752-9980-2BEB6957E258Q46721176-DAE10AD6-FC79-44CD-A6C9-6A8B7D1AA447Q49072873-B1829E71-5C72-4CFC-94E7-C57DBD59D307Q54505356-B4137464-FC2E-4A33-BD86-C46B7716B624Q56345117-E4273629-6A34-48A3-BBF7-07DDC8C1AFE1Q57022275-6FA84BB6-2428-4C5A-A944-7ACF04C885EF
P2860
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.
@en
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.
@nl
type
label
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.
@en
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.
@nl
prefLabel
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.
@en
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.
@nl
P2093
P2860
P50
P1433
P1476
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.
@en
P2093
Charles Koller
Deborah Kennedy
Mark Brandt
Miloslav Beran
P2860
P304
P356
10.1016/J.LEUKRES.2009.10.001
P50
P577
2009-10-29T00:00:00Z